Assyro AI

FDA Orange Book · active-ingredient family

Cisapride monohydrate

Cisapride monohydrate is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:PROPULSID QUICKSOLV · NDA 020767

3

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · suspension, tablet, tablet, orally disintegrating

ProductApplicantApplicationTEApproved
PROPULSID QUICKSOLVJANSSEN PHARMANDA 020767Nov 07, 1997
PROPULSIDJANSSEN PHARMSNDA 020398Sep 15, 1995
PROPULSID×2JANSSEN PHARMSNDA 020210Jul 29, 1993

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Cisapride monohydrate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.